1. CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent
- Author
-
Brendan L.C. Kinney, Brianna Brammer, Vikash Kansal, Connor J. Parrish, Haydn T. Kissick, Yuan Liu, Nabil F. Saba, Zachary S. Buchwald, Mark W. El-Deiry, Mihir R. Patel, Brian J. Boyce, Azeem S. Kaka, Jennifer H. Gross, H. Michael Baddour, Amy Y. Chen, and Nicole C. Schmitt
- Subjects
CD28 ,CD57 ,cellular senescence ,costimulation ,head and neck cancer ,KLRG1 ,Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer. Functional studies confirmed that these cells have enhanced ability to degranulate and produce IFN-γ. They also retain the ability to proliferate, thus are not senescent. These data suggest that CD27/28-CD57+ CD8+ T cells are a subset of highly differentiated, CD45RA+ effector memory (TEMRA) cells with retained proliferative capacity. Patients with > 34% of these cells among CD8+ T cells in the blood had a higher rate of locoregional disease relapse, suggesting these cells may have prognostic significance.
- Published
- 2024
- Full Text
- View/download PDF